Abbott, the leader in the US infant formula market, initiated a voluntary recall of its products in February 2022, following reports of serious bacterial infections in four infants. Abbott’s crisis added to the woes in a market already challenged by pandemic supply-chain issues. Though the situation is unfortunate, it does present Reckitt, the number two, with an opportunity to take market share in a highly profitable market. Importantly, this is a sticky market.
31 May 2022
Abbott’s loss is Reckitt’s gain
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Abbott’s loss is Reckitt’s gain
Reckitt Benckiser Group plc (RKT:LON) | 4,389 5442.4 2.9% | Mkt Cap: 30,981m
- Published:
31 May 2022 -
Author:
Virendra Chauhan -
Pages:
3
Abbott, the leader in the US infant formula market, initiated a voluntary recall of its products in February 2022, following reports of serious bacterial infections in four infants. Abbott’s crisis added to the woes in a market already challenged by pandemic supply-chain issues. Though the situation is unfortunate, it does present Reckitt, the number two, with an opportunity to take market share in a highly profitable market. Importantly, this is a sticky market.